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Bone metastasis is common in lung cancer patient and
the diagnosis of bone metastasis is usually made by using
imaging techniques, especially bone scintigraphy. However,
the diagnostic yield from bone scintigraphy is limited. The
aim of this study is to assess the clinical usefulness of
urinary pyridinoline cross-linked N-telopeptides of Type I
collagen (NTx), urinary deoxypyridinoline (DPD), and
serum alkaline phosphatase (ALP) in the assessment of
bone metastasis in patients with lung cancer. Urinary NTx,
DPD, and serum ALP were measured in 151 lung cancer
patients (33 with and 118 without bone metastasis). Lung
cancer patients with bone metastasis had a higher urinary
excretion of NTx and DPD, and a higher serum ALP than
those without bone metastasis. NTx had a better receiver
operating characteristic (ROC) curve than DPD and ALP,
since the areas under the ROC curve were 0.82, 0.79, and
0.71, respectively. Although correlation coefficients among
NTx, DPD and ALP were significantly positive (p < 0.005),
the strongest relationship was appeared between NTx and
DPD (R=0.616). In conclusion, our results showed the
utility of the new bone markers in detecting bone metastasis
and suggested that measurement of urinary NTx was valid
diagnostic method of bone metastasis from lung cancer.
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INTRODUCTION
In lung cancer, bone metastasis is present in
more than 20% of patients at initial presentation
1
and accurate evaluation of metastatic bone in-
volvement is important in determining the thera-
peutic strategies. Therefore, reliable methods to
detect metastasis are required for tumor-staging
and follow-up of the disease. Bone metastasis is
usually determined initially with bone scinti-
graphy screening, and further evaluation with
bone X-ray and/or magnetic resonance imaging
(MRI). Bone scintigraphy is sensitive for the detec-
tion of bone metastasis.
2,3 However, the false posi-
tive rate is reported to be 40-50%.
3 Plain radio-
graphy is specific but insensitive because nearly
50% of bone mineral must be lost for bone metas-
tasis to be detected.
4 MRI, one of the best diag-
nostic techniques, is inadequate for initial
screenings because of its high cost. Thus, the
development of precise and useful markers is
needed. In recent years, new biochemical markers
of the remodeling process in bone have become
available. Among the new biochemical marker of
bone turnover, bone specific alkaline phosphatese
reflects bone formation, while urinary deoxypyri-
dinolie (DPD), and urinary pyridinoline cross-
linked N-telopeptides of Type I collagen (NTx)
reflect bone resorption. These biochemical
markers of bone turnover are believed to be useful
in the diagnosis of many metabolic diseases
5,6 and
have been reported to be valuable in investigating
bone metastasis from breast cancer,
7 prostate
cancer
8,9, and multiple myeloma.
10 In this study,
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we investigated the usefulness of urinary pyridi-
noline cross-linked N-telopeptides of Type I col-
lagen (NTx), urinary deoxypyridinoline (DPD), se-
rum alkaline phosphatase (ALP) in the assess-
ments of bone metastasis in patients with lung
cancer.
MATERIALS AND METHODS
Patient population
One hundred fifty one ambulatory patients with
lung cancer who were admitted to the Yonsei
University College of Medicine, Severance Hos-
pital in Seoul, Korea between October 2002 and
July 2003 were studied. Thirty-three patients with
bone metastasis and 118 patients without bone
metastasis were included in this study. None of
the patients in the study had received any antine-
oplastic therapy (Chemotherapy or radiotherapy).
The median age was 62 years (range, 28 to 84
years); 105 patients were male and 46 patients
were female. The diagnosis of lung cancer was
confirmed cytologically or histologically. The pa-
tients who had humoral hypercalcemia associated
with malignancy, hyperparathyroidism, hypopa-
rathyroidism, hyperthyroidism, traumatic fracture
(within 6 months), renal failure, or previous bis-
phosphonate treatment were excluded from this
study. All patients gave their informed consent to
the diagnostic procedures.
Bone metastasis evaluation: All patients were
evaluated for bone metastasis by bone scinti-
graphy. A total of 25 mCi 99mTechnetium methy-
lene diphosphonates (MDP) was injected intrave-
nously, and front and back images of the whole
body were taken after 3 hours. The apparatus
used was a double-detector gamma camera
(VERTEX, ADAC Co., CA, USA). Bone scintigraphy
was read by two radiologists and classified into
either a bone metastasis-positive or a negative
group. When the bone scintigraphic interpreta-
tion differed among radiologists, positive scans
were further assessed by additional radiographs;
computerized tomography, magnetic resonance
imaging, positron emission tomography or bone
biopsy, except when the increased uptake was
recognized as being due to a benign condition.
Biochemical analysis: Urine NTx, DPD and
serum ALP were measured within 10 days after
the bone scintigraphic examination in all cases.
For NTx and DPD measurements, a 2-hour urine
collection was obtained after first morning urine
was voided, and then preserved frozen at -20 .
Urinary concentration of DPD was determined
using a radioimmunoassay according to the man-
ufacturer's instructions (Gamma-BCT DPD kit;
Immunodiagnostic Systems, Boldon, England) and
urinary NTx was calculated by competitive immu-
noassay (Vitros
TM NTx reagent pack; Ortho-clini-
cal Diagnostics, Inc., Rochester, NY). Alkaline
phosphatase was assayed by Beckman LX 4201
automated analyzer (Beckman Coulter Inc, CA,
USA) using p-nitrophenyl phosphate as substrate.
The values for urinary DPD and NTx were cor-
rected for urinary creatinine to overcome confoun-
ding variables such as body mass index and urine
dilution. The reference ranges for DPD and NTx
taken from normal populations were 2.5-5.5 and
6-94 mol/mol creatinine, respec μ tively. The re-
ference range for ALP was 38-115 IU/L.
The statistical analysis: The difference between
the mean values of the two groups was evaluated
by Student's t-test and linear regression with
Pearson's correlation coefficients. The relative
effectiveness of the diagnostic tests was assessed
by plotting the true-positive (sensitivity) vs false-
positive (1-specificity) ratios on receiver operating
characteristic (ROC) curves. To evaluate the inde-
pendent contributions of DPD, NTx, and ALP in
predicting bone metastasis, correlation coefficients
were calculated. A p value < 0.05 was considered
statistically significant.
RESULTS
Sixteen cases (10.7%) of bone scintigraphic inter-
pretation differed among radiologists. The discre-
pancies found were further assessed by additional
radiographs; computerized tomography (5 cases),
magnetic resonance imaging (8 cases), positron
emission tomography (3 cases).
Descriptive statistics of bone markers from in-
dividual cancer patients with and without clinical
evidence of bone metastasis are presented in Table
1. The mean urinary concentrations of DPD inSang-Jun Na, et al.
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lung cancer patients with and without bone
metastasis were 13.1 ± 1.1 mol/mol creatinine μ
and 7.4±0.4 mol/mol creatinine, respectively ( μ p
value=0.001). The mean urinary concentrations of
NTx in lung cancer patients with and without
bone metastasis were 120.3 ± 23.6 mol/mol cre μ -
atinine and 50.7 ± 2.3 mol/mol creatinine, respec μ -
tively (p value=0.015). Serum marker of bone for-
mation, ALP, also displayed a higher mean con-
centration in the group with bone metastasis than
in the group without bone metastasis (p value=
0.0006). As shown in Fig. 1, plotting the individual
patient's values for DPD, NTx, and ALP showed
that a majority of lung cancer patients with bone
metastasis had high concentrations. In addition,
4% (4 of 118 patients) of the patients without bone
metastasis had NTx concentrations greater than
the upper limit of the reference value. Similar
Table 1. Bone Markers in Lung Cancer Patients with and without Bone Metastasis
With bone metastasis (n=33) Without bone metastasis (n=118) p value
ALP (U/L) 223.5 ± 50.7 93.4 ± 4.9 0.006
DPD ( mol/mol creatinine) μ 13.1 ± 1.1 7.4 ± 0.4 0.001
NTx ( mol/mol creatinine) μ 120.3 ± 23.6 50.7 ± 2.3 0.015
All values are mean ± SE.
Fig. 1. Urinary concentrations of (A) pyridinoline cross-
linked N-telopeptides of Type I collagen (NTx), (B)
deoxypyridinoline (DPD) and (C) serum alkaline phos-
phatase (ALP) in lung cancer patients with and without
bone metastasis. The horizontal bar represents the mean
value and the upper reference limit for these assay is
shown by the broken line.
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patterns were observed with DPD (64%) and ALP
(15%).
Fig. 2 shows the ROC curves of DPD, NTx, and
ALP for the diagnosis of bone metastasis. NTx
showed the best curve characteristics among the
three bone markers, followed by DPD, ALP. For
NTx, the sensitivity (73%) and specificity (84%)
was seen at the cut-off level of 73 μmol/mol cre-
atinine. For DPD, the sensitivity (82%) and speci-
ficity (72%) was seen at the cut-off level of 8.3 μ
mol/mol creatinine. For ALP, the sensitivity (70%)
and specificity (70%) was seen at the cut-off level
of 90U/L. The areas under the ROC curve were
0.82, 0.79, and 0.71, respectively.
The correlation among DPD, NTx and ALP in
patients with lung cancer are shown in Fig. 3. Al-
though all correlation coefficients were signifi-
cantly positive (p < 0.005), the strongest relation-
ship was between NTx and DPD (R=0.616, Fig.
3C).
DISCUSSION
The initial diagnosis of bone metastasis is usu-
ally made with bone scintigraphy, but its use is
limited due to high cost, false positive rate, and
Fig. 2. Receiver operating characteristic curves of urinary
pyridinoline cross-linked N-telopeptides of Type I colla-
gen (NTx, - -), deoxypyridinoline (DPD, - -), and serum
alkaline phosphatase (ALP,- -) in the diagnosis of bone
metastasis. The areas under the receiver operating charac-
teristic curves for NTx, DPD, and ALP were 0.82, 0.79,
and 0.71, respectively.
Fig. 3. (A) Correlation of urinary pyridinoline cross-
linked N-telopeptides of Type I collagen (NTx) and
serum alkaline phosphatase (ALP) levels in lung cancer
patients (correlation coefficient [R]=0.588; p=0.001). (B)
Correlation of urinary deoxypyridinoline (DPD) and
serum ALP levels in lung cancer patients (R=0.503;
p=0.001) (C) Correlation of urinary NTx and DPD levels
in lung cancer patients (R=0.616; p=0.001).
A
B
CSang-Jun Na, et al.
Yonsei Med J Vol. 46, No. 3, 2005
the inconvenience of using radioactive substances.
Repeatedly monitoring bone metastasis with it
during treatment cause even more problems. Until
now, serum alkaline phosphatase has been used
as an alternative tool to monitor bone metastasis,
but it lacks specificity. ALP is produced not only
by osteoblasts but also by various organs, such as
the liver, small intestine and placenta, and eleva-
tion of its level is not specific to identifying bone
metastasis. Bone-specific alkaline phosphatase,
which is an isoenzyme of ALP derived from bone,
seems to be more specific in bone metastasis than
ALP.
11
Urinary hydroxyproline, another marker of
bone metastasis, also lacks specificity because it
exists not only in bone, but also in elastine and
complement, and its measurement is interfered by
diet. More convenient and less expensive method
with good sensitivity and specificity to detect
bone metastasis has been sought.
Several new biochemical markers of bone turn-
over have been developed, and they are being
tested as a marker of bone metastasis. Deoxypyri-
dinoline (DPD), one of such markers, is distri-
buted mostly in bone collagen, has a higher speci-
ficity for bone than pyridinoline, is excreted in
urine, and is not affected by diet, not metabolized
internally. Therefore, it is expected that its mea-
surement in urine may be more useful for moni-
toring bone resorption than pyridinoline. The
pyridinium cross-links in DPD are nonreducible
collagen cross-links within the extracellular bone.
They are released with the breakdown of bone
and appear to show promise as specific markers
of bone degradation. Pyridinoline is abundant in
bone and cartilage, whereas DPD appears to be
present in significant amounts only in bone.
12 The
cross-linked N-telopeptides are Type I collagen
breakdown products that are specific for bone
discovered in the urine.
They elevate in patients with various metabolic
bone diseases, including Paget's disease, osteo-
porosis, and primary hyperparathyroidism,
13 and
it was reported that they were useful for moni-
toring patients with metastatic bone disease
originating from prostate carcinoma,
8,9 and breast
carcinoma.
7 Demers et al., evaluated seven bio-
chemical markers of bone formation and resorp-
tion in 94 patients with malignant disease in-
cluding bone metastasis, and among those
markers urine NTx showed the most promising
result,
13 which is compatible with our results.
However, in patients with lung carcinoma, there
were little reports showing the clinical utility of
these new markers.
14-16 We found that lung cancer
patients with bone metastasis had significantly
higher concentrations of urine DPD, NTx, and
serum ALP than patients without metastasis.
Among those markers, urinary NTx was the most
reliable biochemical indicator of bone metastasis.
We also noted that some of patients without
documented bone metastasis exceeded the upper
reference limit for this assay. If this reflected
subclinical bony involvement not yet resolved by
bone scintigraphy, these markers might detect
disseminated disease earlier than by bone scinti-
graphy. This would alter the treatment strategy
and improve the disease morbidity caused by
bone metastasis, but further studies are needed to
confirm this. In addition, an important advantage
of these biochemical bone markers over that of
bone scintigraphy lie in their ability to monitor
bone metastasis more quickly.
During the study we found that these new
markers were better than alkaline phosphates, but
also had some problems. Significant differences in
urine NTx and DPD were observed between the
bone metastasis-positive and negative groups, but
the variance in values between the 2 groups
overlapped, as shown in Fig. 1. These results illus-
trated the difficulties associated with diagnosing
the presence or absence of bone metastasis solely
by urinary analysis of NTx and DPD.
We conclude that NTx was superior to other
biomarkers such as ALP, DPD in detecting bone
metastasis in patients with lung carcinoma. The
application of these results can be applied to in-
dicate the need to perform other radiographic
evaluations such as bone scintigraphy. We feel
that further studies with larger numbers and
additional information on follow up are needed.
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